Specialty Pharmacy

The FDA has announced its approval of avatrombopag (Doptelet, AkaRx) tablets to treat low blood platelet count in adults with chronic liver disease (CLD) who are scheduled to undergo a medical or dental procedure.

Patients with glucocorticoid-induced osteoporosis on glucocorticoid therapy who received denosumab (Prolia) had greater gains in bone mineral density in a phase 3 trial.

Officials with the FDA alerted health care professionals about reduced efficacy for some patients taking pembrolizumab (Keytruda) and atezolizumab (Tecentriq) for metastatic urothelial cancer in ongoing clinical trials.

Top news of the day from across the health care landscape.

Antibiotic-resistant Acinetobacter baumannii infections put children with compromised immune systems in health care settings at greater risk of infections of the lung, urinary tract, and other sites.

Pharmacies are increasingly using collected health data to target advertising to customers or identify needs and purchase patterns.

Mepolizumab (Nucala) consistently improves exacerbation reduction and asthma control in patients with severe eosinophilic asthma.

Opioid-related pharmaceutical payments were associated with an increase in the number of opioids prescribed.

Top news of the day from across the health care landscape.

Matthew Hughes, director of Business Development for the Accreditation Commission for Health Care (ACHC), discusses the growth of pharmacy accreditation offerings.

Top news of the day from across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

Erenumab-aooe (Aimovig, Amgen) is the first FDA-approved preventive migraine treatment in a new class of drugs that work by blocking the activity of the molecule that is involved in migraine attacks.

A look at last week's top stories in the world of pharmacy.

Deprivation in patients with chronic obstructive pulmonary disease (COPD) is associated with increased emergency healthcare use, healthcare costs, and mortality rates, according to research.

Dupilumab (Dupixent) significantly improved disease severity in patients aged 12 to 17 years with moderate-to-severe atopic dermatitis.

Community Oncology Alliance survey indicates concern that Medicare Part B reforms will have a negative effect on patient care and drive up costs.

Data from two phase 3 studies showed that esketamine nasal spray demonstrated improvements in depressive symptoms for patients who did not respond to other antidepressant treatments.

Top news of the day from across the health care landscape.

COPD prevalence is increasing more rapidly in women, particularly in younger women, and COPD-related hospitalizations and deaths in women also surpass men.

At the National Community Oncology Dispensing Association's (NCODA) 2018 Spring Summit, Julianne Orr, PharmD, from Indiana University Health Simon Cancer Center, discusses the pharmacist's role in managing adherence to oral treatment regimens for patients with cancer.

Eli Lilly’s galcanezumab met its primary endpoint in a phase 3 study evaluating its use in the prevention of episodic cluster headaches.

Top news of the day from across the health care landscape.

The FDA has approved once-daily oral emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (Truvada) in combination with safe sex practices, to reduce the risk of sexually acquired HIV-1 in at-risk adolescents..

Retacrit gains FDA approval as a biosimilar to Epogen/Procrit for the treatment of anemia caused by chronic kidney disease, chemotherapy, or in patients with HIV.

The trial’s primary endpoint was a statistically significant reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD).

A new study questions medical marijuana’s role in reducing opioid use.

Top news of the day from across the health care landscape.

Officials with the FDA announced the approval subcutaneous formulation of tocilizumab (Actemra) for treatment of active polyarticular juvenile idiopathic arthritis (PJIA) in patients 2 years of age and older.

Significant savings on biologic drugs from biosimilars may not be realized until litigation regarding patents is settled.